Table 2.
Cytokines and IgA levels in fecal samples of healthy controls and patients with irritable bowel syndrome (IBS) at baseline and after supplementation of a product comprising lactobacilli supplemented with larch arabinogalactan and colostrum.
| Patients with IBS | Healthy Controls | IBS vs. Healthy | ||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | After | p, Baseline vs. After | Baseline | After | p, Baseline vs. After | p, Baseline | p, After | |
| IL-6, pg/mL | 3.8 ± 0.4 (0.23–8.43) |
3.5 ± 0.3 (1.1–6.7) |
0.587 | 5.6 ± 0.2 (3.9–6.75) |
3.1 ± 0.1 (2.3–5.5) |
<0.001 | 0.001 | 0.319 |
| IFN-γ, pg/mL | 6.4 ± 3.9 (0–69.5) |
1.7 ± 0.9 (0–15.8) |
0.499 | 73.2 ± 2.6 (55.5–92.5) |
43.6 ± 3.9 (28.3–99) |
<0.001 | <0.001 | <0.001 |
| TNF-α, pg/mL | 25.8 ± 14 (0–214) |
6.0 ± 4.4 (0–82.5) |
0.173 | 36.8 ± 9.6 (0–116.5) |
25.6 ± 7.5 (0–103.3) |
0.215 | 0.022 | 0.001 |
| IL-10, pg/mL | 1.6 ± 0.7 (0–11.3) |
4.3 ± 2.7 (0–53) |
0.441 | 35.4 ± 8.4 (2.5–178) |
24 ± 5 (7.8–108.8) |
0.135 | <0.001 | <0.001 |
| IL-17A, pg/mL | 80.2 ± 26.6 (0–478) |
96.7 ± 36.3 (0.3–613.1) |
0.313 | 70.6 ± 25.5 (0–387) |
69.9 ± 23 (0–100.1) |
0.795 | 0.447 | 0.465 |
| Secretory IgA, μg/mL | 3671.2 ± 738 (0–8406.9) |
3334.4 ± 721 (0–8458.75) |
0.691 | 3001.5 ± 599 (207.5–8355.63) |
2806.4 ± 622.3 (183.75–8818) |
0.747 | 0.485 | 0.583 |
Results are presented as mean concentration (pg/mL or µg/mL) ± SD (range).